Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | TAF1 | P21675 | 6/20 | 0.39 |
| ▸ | CECR2 | Q9BXF3 | 6/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 6/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19652217 | 0.87 | HRH4 (0.40) | LOXL2HRH4JAK2PKMTAF1 | |
| SCHEMBL19658407 | 0.78 | CYP2C19 (0.52) | MAP4K4HRH4OPRD1TAF1CECR2 | |
| SCHEMBL19658497 | 0.78 | MAP4K4 (0.45) | MAP4K4HRH4OPRD1TAF1CECR2 | |
| SCHEMBL19658786 | 0.78 | TAF1 (0.51) | MAP4K4HRH4JAK2OPRD1TAF1 | |
| SCHEMBL19658510 | 0.74 | OPRD1 (0.47) | MAP4K4HRH4JAK2OPRD1TAF1 | |
| SCHEMBL19658782 | 0.74 | TAF1 (0.54) | MAP4K4JAK2OPRD1TAF1CECR2 | |
| SCHEMBL19658736 | 0.74 | GPR119 (0.52) | MAP4K4OPRD1TAF1CECR2BRD9 | |
| SCHEMBL19658507 | 0.72 | CYP1A2 (0.60) | MAP4K4LOXL2HRH4OPRD1TAF1 | |
| SCHEMBL19658512 | 0.72 | TAF1 (0.56) | MAP4K4OPRD1TAF1CECR2BRD9 | |
| SCHEMBL19658509 | 0.71 | TAF1 (0.45) | MAP4K4JAK2OPRD1TAF1CECR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | MAP4K4 1182/4885LOXL2 4297/4885HRH4 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.